drugset / Trial / NCT00322075

LANCGMS - Lantus Continuous Glucose Monitoring Subcutaneous

NCT00322075 ↗

Phase 4 Completed 35 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Comparison of incidence of hypoglycaemic events and glycaemic fluctuations in diabetic patients with basal substitution with NPH insuline versus insuline glargine. Evaluation of HbA1c, FBG (Fasting Blood Glucose), BMI (Body Mass Index), dose of insulin, ratio of basal and prandial insulin, satisfaction with treatment, incidence of adverse events.

Timeline

Start
2006-04
Primary completion
—
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin glargine Protein / enzyme biologic — —

Indications